atrial natriuretic peptide

Description Results NMA

all cause death 1.48 [0.31; 7.03]

nesiritide(0.015 and 0.030 microg/kg/min (n=85)

vs.

placebo (n=42)

Sample size: 85/42

Primary endpoint:

FU duration:

intravenous nesiritidefor 3 hours (n=204)

vs.

placebo (n=142)

3rd arms with IV nitroglycerin for 3 hours(n=143)

double-blind

Sample size: 204/142

Primary endpoint:

FU duration:

nesiritide(0.015 and 0.030 microg/kg/min (n=203)

vs.

usual care (n=102)

open

Parallel groups

Sample size: 203/102

Primary endpoint:

FU duration: <5 days

all cause death 1.56 [0.80; 3.04]

nesiritideinfusion for 24 hours (n=280)

vs.

nitroglycerin (n=218)

Sample size: 280/218

Primary endpoint:

FU duration:

nesiritide(0.015 or 0.03 microg/kg/min) (n=-9)

vs.

Dobutamine (> or =5 microg/kg/min) (n=-9)

open

Parallel groups

Sample size: -9/-9

Primary endpoint: ECG Holter

FU duration: